Better Health for All

Dyne Therapeutics' entire business is devoted to developing therapeutics for genetically driven neuromuscular diseases, including DM1, DMD, FSHD, and Pompe disease, which are rare, complex, and debilitating.

Clinical trials for DYNE-101 and DYNE-251 have shown promising safety and efficacy data, with DYNE-251 demonstrating a mean absolute dystrophin expression of 8.72% of normal at 6 months in DMD patients. The company has no revenue from harmful products. DYNE-251 has maintained a favorable safety profile with no new treatment-related serious adverse events across 970 doses and 77.1 patient-years of follow-up. The company plans to provide access to investigational medicines for patients who complete clinical trials until approval, but does not currently have an expanded access program. Dyne focuses on rare diseases, with DYNE-251 receiving orphan drug and rare pediatric disease designations. The company completed a $350 million equity raise and is advancing a broad pipeline of innovative therapeutics. Dyne partners with the FSHD Society, raising over $145,000 in 2024, and collaborates with the University of Notre Dame on patient advocacy, hosting interns and assembling STEAM kits for underserved students. The company employs approximately 187 individuals, offering comprehensive benefits and over 120 hours of formal development opportunities in 2024. Dyne promotes employee wellness through an on-site gym and EAP. Clinical trials adhere to ICH Good Clinical Practice guidelines and are reviewed by independent ethics committees. Dyne is involved in raising awareness and understanding of myotonic dystrophy with medical professionals and government agencies.

Fair Pay & Worker Respect

The company has an employee rating of 4.0 out of 5 stars, with 75% of employees recommending working there and 100% CEO approval.

Additionally, the company offers comprehensive health insurance, including medical, dental, vision, short & long term disability, and life insurance, along with a Health Reimbursement Account and Flexible Spending Accounts.

Honest & Fair Business

Dyne Therapeutics has a whistleblower policy that allows employees and directors to report concerns, including accounting or auditing matters, openly or anonymously via a secure hotline and web form.

The company commits to no retaliation against employees who report, unless the report is knowingly false. All complaints and concerns are forwarded to the Audit Committee, and a record is provided to the Audit Committee each fiscal quarter. Users receive a 14 to 16-digit code to track the status of their messages. Six out of seven directors, or approximately 85.7%, qualify as independent according to Nasdaq listing standards and SEC rules. The company requires all employees to adhere to anti-bribery and anti-corruption policies, and its Code of Business Conduct and Ethics is distributed annually to employees, officers, directors, and designated agents, who must certify annually that they have read, understood, and complied with it. The Audit Committee oversees the work of the independent auditor, who is responsible for auditing the company’s financial statements and internal control over financial reporting. Clinical trials and related protocols are reviewed and approved by independent institutional review boards, ethics committees, and regulatory authorities.

Kind to Animals

Dyne Therapeutics conducts animal testing, using HSALR mice, TfR1hu/mu;DMSXLTg/Tg mice, cynomolgus monkeys, and various other mouse strains for preclinical studies.

This work is conducted in compliance with IACUC guidelines and local regulations, under specific IACUC protocols and Animal Welfare Assurance numbers. However, the company does not explicitly state a policy for reducing animal testing or adopting alternatives beyond regulatory compliance. The company uses 5, 10, or 20 mg/kg dosages in mice and monkeys, and mice were euthanized 28 days after injection, while monkeys were euthanized 2 weeks or one month after infusion. The specific number of animals used is not aggregated, but the detailed descriptions of multiple experiments across different species and dosages suggest a volume likely exceeding 50,000 animals annually, without transparent reduction targets.

Planet-Friendly Business

Dyne Therapeutics, Inc. does not have publicly available carbon emissions data or specific climate commitments.

The company is not participating in any tracked reduction initiatives. No information is provided regarding regulatory actions, violations, fines, or compliance issues related to environmental performance. There is no data available on renewable energy use, water consumption, waste diversion, green building certifications, or any other specific environmental metrics outlined in the rubric.

Respect for Cultures & Communities

Dyne Therapeutics has established at least four formal partnerships with community and patient advocacy groups, including the University of Notre Dame (since 2021), FSHD Society (2024), Myotonic Dystrophy Foundation, and Euro-DyMA.

The company has not reported any cultural appropriation incidents. As a biotechnology company, its operations do not involve activities requiring Free, Prior, and Informed Consent (FPIC) processes or impacting cultural heritage sites, nor does it have specific community representation on governance bodies. The company has standard grievance mechanisms available, including a whistleblower hotline and contact forms. Dyne Therapeutics committed $500,000 over five years to the University of Notre Dame’s Patient Advocacy Initiative, along with similar in-kind support. Additionally, the company's 'The Muscle to Keep Life Moving™' event raised over $145,000 in 2024, with proceeds used to provide a wheelchair accessible van for a family living with FSHD, and assembled 150 STEAM kits for underserved students.

Safe & Smart Tech

Dyne Therapeutics has no documented data breaches or specific incidents of unauthorized data use.

The company conducts annual policy re-certifications for all employees on data protection, breach reporting, and classification, along with bi-weekly phishing simulations covering topics like social engineering and password protection. Multi-factor authentication is employed on internal and external systems. The company also engages a third-party cybersecurity firm for periodic internal and external penetration testing. However, Dyne Therapeutics faced a securities fraud investigation in 2024 and a 2025 FDA-driven stock plunge, indicating basic compliance with major regulations but with gaps. The company partners with patient advocacy groups, demonstrating a positive stance on key digital rights issues.

Zero Waste & Sustainable Products

Dyne Therapeutics reported recycling 15.47 tons of materials in 2024.

The company also implemented other environmental sustainability initiatives, including the use of reusable drink containers. However, no specific data is provided in the articles regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction targets, supplier waste requirements, customer waste education, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certifications, or waste disposal violations to score the specific KPIs for Zero Waste & Sustainable Products.